Current standard-of-care treatments focus primarily on preventing secondary damage through surgical intervention and supportive care
The cheapest peptides available aren't worth the risk
Comprehensive review of BPC-157 safety data including discussion of theoretical cancer concerns
KPV: CAS 67763-96-6 | MW ~358.4 g/mol
Chang CH, Tsai WC, Lin MS, et al
For years, most care leaned on a small set of options like minoxidil and finasteride, plus procedures, so the field became focused on optimization rather than entirely new pathways. Immune-mediated hair loss conditions such as alopecia areata (AA) have seen more recent advances, but even here, durable and well-tolerated options remain limited